Entitled "Successful new drug candidate for patients with bladder cancer – from discovery to the clinic", it describes the discovery of the tumoricidal protein-lipid complex HAMLET and how that discovery has led to a family of potential drug candidates, such as the synthetic drug candidate, Alpha1H, that has been successfully tested in clinical trials in bladder cancer patients.

Guardian Media Group (theguardian.com) is amongst the world’s leading media organisations with a progressive, global, audience and is one of the largest English-speaking quality news websites in the world. It is also one of the leading national newspapers in the UK and internationally. Hamlet Pharma was selected by MediaPlanet, the media agency for The Guardian, to be featured in the Health special given the innovative work conducted by the company to date.

Read the supplemented full article in The Guardian here:  https://bit.ly/3FdVPeG

For more information, contact

Catharina Svanborg, Chairman and founder of Hamlet Pharma, +46-709 42 65 49

Catharina.svanborg@med.lu.se

Martin Erixon, CEO of Hamlet Pharma, +46-733 00 43 77

martin.erixon@hamletpharma.com

About HAMLET Pharma

HAMLET Pharma, listed on Spotlight Stockmarket, develops new drugs for the treatment and prevention of cancer, based on the discovery of the tumoricidal protein-lipid complex, HAMLET. HAMLET has shown therapeutic efficacy in animal models and effects in clinical proof-of-concept studies. The Alpha1H peptide drug candidate, reproduces the effects of HAMLET and has demonstrated therapeutic efficacy in patients with bladder cancer, where cinical trials are ongoing. Bladder cancer is a common and costly form of cancer, with few successful new treatment options. The company is further exploring the use of Alpha1H for other cancer indications, including brain tumors. In addition, Hamlet Pharma develops BAMLET, which is a HAMLET-like complex formed by bovine α-lactalbumin. Data from animal models show promising effects of local BAMLET treatment against colon cancer.